Pharmaceuticals

Global Onchocerciasis Treatment Market 2026–2035 supported by global health initiatives and disease eradication programs

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Onchocerciasis Treatment Market From 2026 To 2030?

The onchocerciasis treatment market has experienced robust growth recently. This market is projected to expand from $1.11 billion in 2025 to $1.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Factors contributing to its historical expansion include the restricted access to ivermectin and doxycycline in areas where the disease is prevalent, a reliance on hospital-centric distribution channels, insufficient understanding of onchocerciasis management, shortcomings in preventive chemotherapy initiatives, and an exclusive reliance on oral drug formulations.

The onchocerciasis treatment market size is anticipated to experience robust growth in the upcoming years, with an expected increase to $1.59 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%. The expansion projected for this period can be attributed to several factors, including the introduction of moxidectin and long-acting formulations, the broader availability through online and retail pharmacy distribution, the development of combination therapies, augmented funding from governments and NGOs for eradication initiatives, and the implementation of community-based preventive approaches. Key trends identified for the forecast period involve the broadening of mass drug administration (MDA) programs, the creation of pediatric and fixed-dose formulations, an increased emphasis on anti-Wolbachia therapies, the integration of both oral and injectable treatment regimens, and the growth of treatment campaigns supported by communities and governments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

What Drivers Are Influencing The Onchocerciasis Treatment Market?

An anticipated increase in individuals experiencing eye-related conditions is projected to fuel the expansion of the onchocerciasis treatment market in the coming years. These eye-related problems encompass diverse ailments impacting sight and ocular well-being, such as infections, injuries, and persistent conditions like glaucoma or cataracts. This increase in patients with eye conditions is largely attributed to elevated screen usage and extended contact with digital screens. Treatment for onchocerciasis aids in averting and handling sight impairment and blindness by eradicating the parasitic infection responsible for ocular tissue inflammation and damage. For example, data from May 2024, provided by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that approximately 20.5 million Americans aged over 40 had cataracts in at least one eye, representing 17.2% of that demographic. Projections suggest that close to 30 million individuals will develop cataracts by 2028. Consequently, the growing occurrence of conditions affecting the eyes is fueling expansion within the onchocerciasis treatment market.

Which Segments Are Included In The Analysis Of The Onchocerciasis Treatment Market?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Which Trends Are Impacting The Growth Of The Onchocerciasis Treatment Market?

Leading companies within the onchocerciasis treatment market are concentrating on developing innovative antiparasitic drugs to enhance therapeutic effectiveness and reduce treatment duration. Antiparasitic medications are pharmaceutical agents specifically formulated to eliminate or inhibit parasites like worms and protozoa that cause infections in humans. For example, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets to treat river blindness in individuals aged 4 years and older. This authorization allows Ghana to implement community-based mass drug administration programs utilizing moxidectin, which provides greater efficacy and more prolonged effects compared to ivermectin. With this approval, MDGH aims to broaden access to an effective new treatment for onchocerciasis, thereby enabling large-scale community programs in endemic regions.

Which Key Industry Participants Are Active In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Read the full onchocerciasis treatment market report here:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Onchocerciasis Treatment Market?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Onchocerciasis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795